MTOR and neoplasm with perivascular epithelioid cell differentiation: This trial investigated nab-sirolimus, a nanoparticle-albumin bound formulation of sirolimus in patients with metastatic, unresectable PEComas of any anatomic site, who had not previously received an mTOR inhibitor.